二硫代氨基甲酸吡咯烷对苦参碱诱导肝癌细胞凋亡的影响

目的 观察二硫代氨基甲酸吡咯烷(PDTC)抑制核因子-κB(NF-κB)活化后对苦参碱诱导肝癌细胞HepG2凋亡的影响.方法 MTT法观察苦参碱(分0.8、1.0、1.5、2.0、2.5 g/L组)及PDTC联合苦参碱对HepG2细胞增殖的抑制作用.将HepG2细胞随机分为细胞对照组、PDTC组(20μmol/L)、苦参碱组(1.5 g/L)和PDTC+苦参碱联合组,流式细胞仪和末端脱氧核苷酸转移酶介导的脱氧三磷酸尿苷缺口末端标记法检测细胞凋亡;电泳迁移率改变实验检测细胞核内NF-κB的活化水平.结果 PDTC增强了苦参碱对细胞增殖的抑制作用(F=183.92,P＜0.01).苦参碱同时具有诱导HepG2细胞凋亡和NF-κ B活化的作用;PDTC能显著增加苦参碱诱导的HepG2细胞凋亡和抑制苦参碱诱导的HepG2的NF-κB活化,细胞凋亡率由6.11%±0.81%增加至12.95%±0.02%(χ2=9.67,P＜0.05),NF-κB活化的灰度值由38.82±0.17降至32.01±0.69(χ2=10.38,P＜0.05).结论 苦参碱诱导HepG2细胞凋亡的同时激活NF-κB;PDTC可通过抑制NF-κB活化,增强苦参碱诱导HepG2细胞凋亡的作用.     

塞来昔布联合氟伐他汀对人肝癌裸鼠皮下移植瘤生长及细胞凋亡的影响

目的 探讨塞来昔布联合氟伐他汀对实验性人肝癌裸鼠皮下移植瘤生长及细胞凋亡的影响.方法 32只实验裸鼠左腋窝皮下接种BEL-7402肝癌细胞株,随机分为对照组、塞来昔布组、氟伐他汀组及塞来昔布和氟伐他汀联合用药组.实验结束时,留取移植瘤标本,流式细胞术及原位缺口末端标记法检测肿瘤细胞凋亡率,Western blot检测Akt、磷酸化Akt(p-Akt)和survivin蛋白的表达情况.数据比较采用析因设计多因素方差分析及多个样本均数间多重比较的SNK-q检验.结果 联合用药组肿瘤生长明显被抑制,塞来昔布组、氟伐他汀组抑瘤率分别为34.0%和25.0%,联合用药组抑瘤率为72.2%.对照组细胞凋亡指数为3.5%±0.8%,联合用药组为19.4%±3.0%,塞来昔布组和氟伐他汀组分别为8.5%±1.4%和9.4%±1.7%,联合用药组肿瘤细胞凋亡明显高于塞来昔布及氟伐他汀单药组(P值均＜0.01).流式细胞术检测结果显示,移植瘤细胞凋亡率对照组为4.1%±1.6%,塞来昔布组为9.1%±2.1%,氟伐他汀组为10.1%±2.3%,联合用药组为23.6%±5.8%,各单药用药组均高于对照组(P值均＜0.05),其中联合用药组高于对照组及各单药组(P值均＜0.01).Western blot检测结果显示,联合用药组较对照组明显下调p-Akt(0.23±0.08比1.12±0.07)和survivin蛋白(0.50±0.07比1.47±0.19)的表达(P值均＜0.01).结论 与单用塞来昔布或氟伐他汀相比,联合用药能更有效地抑制肝癌细胞生长.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

目的 探讨西罗萸司(SRL)对人肝癌裸鼠肝脏移植瘤生长的影响.方法 建立人肝癌裸鼠肝脏移植瘤模型,使用SRL、他克莫司(FK506)进行干预治疗,采用免疫组织化学方法和图像分析技术检测移植瘤血管内皮细胞生长因子、增殖细胞核抗原的表达和微血管密度,原位末端标记法检测肿瘤细胞凋亡情况.统计学处理采用方差分析或t检验.结果 (1)SRL、FK506组和对照组移植瘤质量分别为(352±38)mg、(683±53)mg、(675±45)mg;SRL组移植瘤质量较对照组明显减少(t=10.378,P<0.01);FK506组和对照组比较无明显差异(P>0.05).(2)SRL组移植瘤血管内皮细胞生长因子和增殖细胞核抗原的表达较对照组明显下凋亡(f值分别为5.753和5.296,P<0.05),FK506组和对照组比较无明显差异(P>0.05).(3)SRL组移植瘤微血管密度较对照组明显减少(t=8.637,P<0.01);FK506组和对照组相比无明显变化(P>0.05).(4)SRL组移植瘤凋亡指数明显高于对照组(t=11.518,P<0.05);FK506对移植瘤凋亡指数无明显影响(P>0.05). 结论 SRL可通过减少肿瘤血管形成、阻I卜肿瘤增殖、诱导肿瘤细胞凋亡抑制肝癌的生长.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

溴隐亭逆转肝癌多药耐药的机制

目的探讨溴隐亭对肝癌多药耐药逆转的作用机制。方法体外实验分亲本细胞HepG2组（A组），耐药细胞HepG2／ADM组（B组）和B组加溴隐亭称为C组。分别检测各组细胞内荧光强度变化，细胞P-糖蛋白、蛋白激酶C—α蛋白表达情况，及5种肿瘤药物半数抑制浓度及耐药指数变化。分别将肝癌细胞HepG2和耐药细胞HepG2／ADM原位种植入裸鼠肝脏内，称A组鼠和B组鼠，另设B组种植鼠给予溴隐亭灌胃治疗称C组鼠。B超观察种植瘤的生长情况，肿瘤大小为1．0cm左右时经腹腔化疗，2周后处死裸鼠计算肿瘤的体积和质量抑制率，观察种植瘤组织多药耐药基因1不敷出mRNA表达情况，及治疗后肝癌细胞的凋亡指数。单独检测24只种植耐药细胞HepG2／ADM的裸鼠在服用溴隐亭前后分别注射的^99mTc—MIBI在肝脏肿瘤部位的潴留情况。结果体外实验结果显示在溴隐亭浓度为10μmol／L时罗丹明123在细胞内的潴留率均明显增加，且呈时间依赖性，对阿霉素的耐药逆转以溴隐亭浓度为10μmol／L时最显著，逆转率为82．6%。蛋白激酶C—α蛋白表达，C组与B组比较差异有统计学意义（q=5．37，P〈0．01），但两组P-糖蛋白表达差异无统计学意义（q=1．86，P〉0．05）。体内试验结果显示种植瘤的体积和质量抑制率比较，C组鼠明显高于B组鼠（q1=5．89，Q=4．92，P〈0．01），接近于A组鼠（功=2．47，q2=3．02，P〉0．05）。C组鼠与B组鼠多药耐药基因1mRNA表达差异无统计学意义（q=3．71，P〉0．05）。化疗后肿瘤细胞凋亡率比较，C组鼠明显高于B组鼠（q=3．72，P〈0．01）。口服溴隐亭后肝肿瘤组织对^99mTc-MIBI的潴留指数明显提高（t=3．58，P〈0．01）。结论溴隐亭通过抑制P-糖蛋白的功能可有效的逆转肝癌多药耐药性。     

索拉非尼联合顺铂对人肝癌裸鼠移植瘤生长的抑制作用

目的探讨多靶点酪氨酸激酶抑制剂索拉非尼联合顺铂（DDP）对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法构建人肝癌细胞HepG2裸鼠皮下移植瘤模型,随机分为空白对照组、溶剂对照组、索拉非尼组、DDP组和联合用药组。观察用药前后肿瘤大小,测体质量,并计算瘤重,绘制肿瘤生长曲线;应用免疫组化检测肿瘤微血管密度（MVD）。结果索拉非尼和DDP单药均能抑制肿瘤生长,两药联合疗效明显增强（P〈0．05）。与对照组和顺铂组相比,索拉非尼组和联合用药组能明显抑制肿瘤血管生成,MVD值均明显降低,以联合用药组最为明显（P均〈0．05）。结论索拉非尼联合DDP能增强抑制人肝癌裸鼠移植瘤的生长及微血管生成。     

染料木黄酮对裸鼠肝癌切除术后肿瘤复发和转移的影响

研究显示,染料木黄酮(又称三羟基异黄酮)有抗前列腺癌、乳腺癌、卵巢癌等实体肿瘤的活性,且不良反应较少[1-2],但未见关于染料木黄酮能否影响肿瘤切除后复发和转移的报道.我们建立了肝癌切除术后肿瘤高转移和复发的裸鼠模型,以探讨染料木黄酮对裸鼠肝癌切除术后肿瘤复发和转移的影响及其机制.     

达肝素钠对肝癌生长转移抑制的实验研究

目的研究低分子肝素达肝素钠对肝癌生长转移的抑制作用。方法采用人肝癌裸鼠转移模型(LCI-D20)。40只模型鼠随机分成4组即对照组、化疗组(顺铂 氟尿嘧啶),达肝素钠组、联合组(顺铂、氟尿嘧啶与达肝素钠)。观察肿瘤大小和转移、抑瘤率、测血清甲胎蛋白(AFP)、肿瘤微血管密度(MVD)、CD31。结果对照组、化疗组、达肝素钠组、联合组的肿瘤体积分别为(25245±13367)mm3、(1610 ±1217)mm3、(5883±3131)mm3和(5556±2570)mm3;抑瘤率分别为0%、93.6%、76.7%和78.0%;MVD 分别为20.7±6.8、18.2±2.6、4.8±1.8和6.5±2.4;CD31分别为31.8±5.7、25.5±5.1、21.6±4.8和19.6±2.4;AFP分别为(121.8±31.4)ng/ml、(21.5±13.3)ng/ml、(75.6±29.7)ng/ml 和(55.8±38.0)mg/ml;肝转移率分别为80%、70%、20%和10%;肺转移率分别为70%、60%、20%和10%; 腹壁转移率分别为90%、60%、30%和30%;腹水形成率分别为20%、10%、0%和0%。化疗组、达肝素钠组、联合组分别与对照组比,对肝癌生长的抑制作用差异有统计学意义,F=9.191,P<0.01。达肝素钠对肝癌血管形成和转移有良好的抑制作用,与对照组及单纯化疗组比差异有统计学意义,F=4.937,P<0.01。结论低分子肝素达肝素钠通过抗肿瘤血管形成,对肝癌的生长与转移有抑制作用。     

小干扰RNA抑制核因子-κB活化对HepG2细胞凋亡的影响

目的 探讨小干扰RNA(SiRNA)抑制核转录因子(NF)-κB活化对肝癌细胞凋亡的影响.方法 化学合成NF-κB siRNA和阴性对照siRNA,脂质体法转染HepG2细胞,用巢式RT-PCR和荧光定量PCR检测NF-κB mRNA表达情况;免疫组织化学法、酶联免疫吸附法、Western b10t检测NF-κB蛋白表达情况;用磷脂结合蛋白V-异硫氰酸荧光素法检测细胞凋亡,分析NF-κB表达抑制和细胞凋亡间关系.多个样本均数间的比较先行方差齐性检验,方差齐时行单因素方差分析;计数资料比较采用确切概率法分析.结果 NF-κBp65 mRNA在HepG2细胞相对表达量为1.13±0.03,在正常肝细胞L02为0.29±0.07,两者比较,t=27.02,P<0.05,差异有统计学意义.利用NF-κB siRNA干扰可下调NF-κB表达,且呈剂量、时间依赖;NF-κB siRNA转染HepG2细胞72h后,NF-κBmRNA和蛋白表达分别下降了93%和62%,抑制NF-κB表达使HepG2细胞凋亡增加85%. 结论 NF-κB在肝癌细胞中高表达,NF-κB SiRNA能特异性抑制其在肝癌细胞中活化并促进癌细胞凋亡发生.     

转移消失蛋白B基因表达对MHCC97H细胞侵袭和转移潜能的影响

目的 观察慢病毒载体携带靶向人源性MTSS1(转移消失蛋白B基因,MIM-B基因)小干扰RNA对人肝癌细胞株MHCC97H细胞侵袭和转移潜能的影响.方法 构建靶向MTSS1基因的慢病毒载体-siMTSS1,转染MHCC97H细胞.实时荧光定量PCR和Western blot用于测定MIM-B mRNA和蛋白表达;侵袭实验用于评估侵袭潜能;明胶酶谱用于检测基质金属蛋白酶2(MMP2)活性.以MHCC97H构建裸鼠原位移植瘤模型,第14天将24只成模裸鼠随机分成空白对照组、空载体组及治疗组(每组8只),在超声引导下瘤周及瘤内多点注射硼酸盐缓冲液、Lenti-GFP及Lenti-siMTSS1,第35天检测肺转移情况.采用SPSS13.0统计软件对计量资料进行方差分析.结果 成功构建慢病毒载体携带的针对MTSS1基因小干扰RNA,Lenti-siMTSS1感染效率为97.0%,显著抑制MIM-B蛋白表达,下调MMP2活性.体外实验结果显示空白对照组、空载体组和干扰组细胞穿膜数分别为37.9±4.4、37.4±5.3和26.6±4.6(F=26.695,P＜0.01).体内实验结果显示空白对照组、空载体组及治疗组肺转移结节数分别为6.5±2.6、6.4±2.7和3.8±1.3(F=3.637,P＜0.05);肿瘤组织MIM-B mRNA相对表达量分别为0.39±0.19、0.38±0.10和0.16±0.11(F=11.644,P＜0.01).结论 慢病毒介导小干扰RNA抑制MIM-B mRNA和蛋白表达进而抑制HCC侵袭、转移潜能可能与下调MMP2活性相关,为肝癌患者提供一条新的分子靶向治疗思路.     

沙利度胺干预核因子-κB活化对肝细胞癌变的影响

我们以2-乙酰氨基芴(2-FAA)诱发鼠肝癌发生,同时给予沙利度胺干预,观察核因子-κB(NF-κB)表达的动态变化及其对肝细胞癌变的影响.